Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: John Zwiener who wrote (385)	7/3/1998 12:00:00 PM
From: James Perry	Read Replies (1) \| Respond to of 1025

Fine, John. Thank you. Helpful information. You inferred, without stressing it, a fact that I doubt is fully appreciated as to the POC market: Once quick testing becomes available to doctors, the number of tests being performed will increase greatly. Well beyond the numbers of tests being presently performed, and that will certainly affect the dollar size of the market. Not necessarily the number of KINDS of tests (though we expect some increase there in the normal course of progress), but some of the tests will be performed repeatedly to measure the progress of ailment or effectiveness of treatment. It really will give the capacity to fine tune treatment, and you know the medical payment boys will support whatever will get one out of the hospital quicker. Now please tell us...am sure you saw the last Rumor Mill and a number of comments made regarding Roche. Do you feel that Roche is an effectively performing partner for Igen? I sort of sensed that they were pushing hard and probably very effectively to market electsys, from the things being said, but there certainly was room for other opinions. I value your opinion. What is it? Let's hope they keep buying. That $3 spike was nice the other day!